Digest

This podcast, featuring nephrologist Dr. Jordy Cohen, delves into the complexities of resistant hypertension. It begins by emphasizing accurate blood pressure measurement using automated cuffs and home monitoring to avoid inaccuracies from "white coat" hypertension. The discussion covers treatment goals (ideally <130/80 mmHg), first-line agents, and strategies for managing diastolic hypertension. Managing resistant hypertension involves adding agents, potentially using triple-pill combinations, while carefully considering the benefits and drawbacks. The podcast explores investigating resistant hypertension by checking medication adherence, confirming the diagnosis, addressing lifestyle factors, and considering secondary causes. Newer agents like aprisotensin and semaglutide, along with those in development (aldosterone synthase inhibitors and siRNAs targeting angiotensinogen), are discussed. Renal denervation procedures, their efficacy, limitations, and role in management are also examined. The episode includes a discussion on diagnosing primary aldosteronism, including the debate on holding medications before testing, and provides referral guidelines for primary care physicians. Finally, the podcast summarizes key takeaways, highlighting the promise of new therapies and the importance of patient education and home blood pressure monitoring. A concluding debate touches upon the relative merits of renal denervation versus novel therapeutics.

Outlines

00:01:27

Introduction to Resistant Hypertension and Guest Introduction

Introduces the podcast hosts and Dr. Jordy Cohen, a nephrologist specializing in hypertension, and the episode's focus on resistant hypertension.

00:04:58

Accurate Blood Pressure Measurement and Hypertension Definition

Defines hypertension and stresses accurate measurement using automated cuffs and home monitoring to overcome limitations of traditional clinic readings.

00:18:55

Treatment Goals and Initial Management Strategies

Discusses treatment goals (<130/80 mmHg), first-line agents, and the use of fixed-dose combinations to improve blood pressure control and patient adherence.

00:25:10

Diastolic Hypertension and Resistant Hypertension Management

Addresses challenges in managing diastolic hypertension and explores strategies for managing resistant hypertension, including adding agents and triple-pill combinations.

00:32:09

Investigating and Addressing Resistant Hypertension

Covers next steps when initial treatments fail: checking medication adherence, confirming diagnosis, addressing lifestyle factors, and considering contributing factors.

00:36:58

Novel Agents and Therapies for Resistant Hypertension

Explores newer agents (aprisotensin, semaglutide) and those in development (aldosterone synthase inhibitors, siRNAs targeting angiotensinogen).

00:53:10

Renal Denervation and its Role in Treatment

Provides a detailed examination of renal denervation procedures, their efficacy, limitations, and potential role in managing resistant hypertension.

01:06:20

Diagnosing Primary Aldosteronism and Referral Guidelines

Discusses diagnosing primary aldosteronism, the debate on holding medications before testing, and guidelines for referring patients with resistant hypertension to specialists. Emphasizes the importance of preliminary testing before referral.

01:12:51

Conclusion: New Therapies and Key Takeaways

Summarizes key takeaways, highlights promising new therapies (aldosterone synthase inhibitors and GLP-1 agonists), emphasizes patient education and home blood pressure monitoring, and concludes with a discussion on renal denervation versus novel therapeutics.

Keywords

Q&A

• What are the key considerations for accurately measuring blood pressure?

  Accurate measurement is crucial; automated cuffs are preferred over manual ones to minimize errors and the "white coat" effect.

• What are the current treatment goals for hypertension?

  Current guidelines generally aim for <130/80 mmHg; resistant hypertension requires a stepwise approach with multiple medications.

• What are some promising new therapies for resistant hypertension?

  Aldosterone synthase inhibitors, GLP-1 agonists, and siRNAs targeting angiotensinogen show promise.

• What is the role of renal denervation in managing resistant hypertension?

  Renal denervation is a procedure that can lower blood pressure, but its efficacy is debated and it's not a cure.

• Should medications be held before testing for primary aldosteronism?

  Holding medication isn't always necessary; a salt load with a 24-hour urine aldosterone test is a useful alternative.

• When should a patient with resistant hypertension be referred to a specialist?

  Referral is suggested for patients with chronic kidney disease, those refractory to multiple medications, or those where medication safety is uncertain.

Show Notes